The impact of diabetes-related 2 lower-extremity amputations in The Netherlands, J Diabetes Complications, vol.10, pp.325-330, 1996. ,
, , 2006.
, Fremantle Diabetes Study. Diabetologia, vol.49, pp.2634-2641
A checklist system to score healing progress of diabetic 7 foot ulcers, Int J Low Extrem Wounds, vol.9, pp.74-83, 2010. ,
Diuretic agents: inciting factor in nonocclusive 9 mesenteric infarction, JAMA, vol.229, pp.1451-1453, 1974. ,
Reversible leg ischaemia due to diuretics, Br Med J, vol.1, pp.11-1114, 1978. ,
Canagliflozin and Cardiovascular 13 and Renal Events in Type 2 Diabetes, N Engl J Med, vol.377, pp.644-657, 2017. ,
, , 2004.
, Antihypertensive drug therapy and the risk of lower extremity amputations in 16 pharmacologically treated type 2 diabetes patients, Pharmacoepidemiol Drug Saf, vol.13, pp.139-146
Graz Critical Limb Ischemia Score: A Risk 18 Score for Critical Limb Ischemia in Peripheral Arterial Occlusive Disease, Medicine, vol.19, p.1054, 2015. ,
Prognostic value of the 21 insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Genetique (DIAB2NEPHROGENE), and Survie, Diabete de type 2 et Genetique 1 (SURDIAGENE) studies, Diabetes Care, vol.31, pp.1847-1852, 2008. ,
A new equation to estimate 3 glomerular filtration rate, Ann Intern Med, vol.150, pp.604-612, 2009. ,
Regression modeling of competing crude failure probabilities, 2001. ,
, Biostatistics, vol.2, pp.85-97
Dual 7 effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice, 2005. ,
, Arterioscler Thromb Vasc Biol, vol.25, pp.65-70
An Introduction to Propensity Score Methods for Reducing the 10 Effects of Confounding in Observational Studies, Multivariate Behav Res, vol.46, pp.399-424, 2011. ,
Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent 12 ,
, Major outcomes in high-risk hypertensive patients randomized to 13 angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The 14, Heart Attack T, 2002.
, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
, JAMA, vol.288, pp.2981-2997
Morbidity and mortality in patients 17 randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic 18 in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment 19 (INSIGHT), Lancet, vol.356, pp.366-372, 2000. ,
, , 2007.
, Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease
, , 2018.
, Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2
, Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for
, Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real
, World). Circulation, vol.137, pp.1450-1459
SGTL2 inhibitors and amputations in the US FDA, 2017. ,
, Adverse Event Reporting System, Lancet Diabetes Endocrinol, vol.5, pp.680-681
SGLT-2 inhibitors and the risk of lower-8 limb amputation: is this a class effect, Diabetes Obes Metab, 2018. ,
, Schumock GT, vol.10, 2018.
, Inhibitors: A Propensity-Matched Cohort Study, Diabetes Obes Metab, vol.12
Risk of lower extremity amputations in 13 people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors 14 in the USA: A retrospective cohort study, Diabetes Obes Metab, vol.20, pp.582-589, 2018. ,
Effects of sodium-glucose cotransporter-16 2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes -A 17 systematic review, Diabetes Res Clin Pract, vol.140, pp.118-128, 2018. ,
Cardiovascular outcomes of sodium glucose 19 cotransporter-2 inhibitors in patients with type 2 diabetes, Diabetes Obes Metab, vol.20, 2018. ,
, , 2018.
, Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among